Table of Contents Author Guidelines Submit a Manuscript
Journal of Nanotechnology
Volume 2016, Article ID 3020361, 18 pages
http://dx.doi.org/10.1155/2016/3020361
Review Article

The Extraordinary Progress in Very Early Cancer Diagnosis and Personalized Therapy: The Role of Oncomarkers and Nanotechnology

1Institute of Translational Pharmacology, National Research Council (CNR), Rome, Italy
2Department of Human and Social Science, Headquarters, National Research Council (CNR), Rome, Italy
3Department of Medical Sciences, University of Torino, Torino, Italy

Received 18 December 2015; Accepted 21 February 2016

Academic Editor: Aws Alshamsan

Copyright © 2016 Marialuigina Fruscella et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. G. de Castro, P. A. Clarke, B. Al-Lazikani, and P. Workman, “Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance,” Clinical Pharmacology and Therapeutics, vol. 93, no. 3, pp. 252–259, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. H. L. McLeod, “Cancer pharmacogenomics: early promise, but concerted effort needed,” Science, vol. 340, no. 6127, pp. 1563–1566, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. T. J. R. Harris and F. McCormick, “The molecular pathology of cancer,” Nature Reviews Clinical Oncology, vol. 7, no. 5, pp. 251–265, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Pirker, F. J. F. Herth, K. M. Kerr et al., “Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop,” Journal of Thoracic Oncology, vol. 5, no. 10, pp. 1706–1713, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. B. W. Newsome and M. S. Ernstoff, “The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived?” British Journal of Clinical Pharmacology, vol. 66, no. 1, pp. 6–19, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Normanno, S. Tejpar, F. Morgillo, A. De Luca, E. Van Cutsem, and F. Ciardiello, “Implications for KRAS status and EGFR-targeted therapies in metastatic CRC,” Nature Reviews Clinical Oncology, vol. 6, no. 9, pp. 519–527, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. R. R. Raval, A. B. Sharabi, A. J. Walker, C. G. Drake, and P. Sharma, “Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer,” Journal for ImmunoTherapy of Cancer, vol. 2, article 14, 2014. View at Google Scholar
  8. E. J. Lipson and C. G. Drake, “Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma,” Clinical Cancer Research, vol. 17, no. 22, pp. 6958–6962, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. J. D. Wolchok, H. Kluger, M. K. Callahan et al., “Nivolumab plus Ipilimumab in advanced melanoma,” The New England Journal of Medicine, vol. 369, no. 2, pp. 122–133, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. E. M. Van Allen, N. Wagle, A. Sucker et al., “The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma,” Cancer Discovery, vol. 4, no. 1, pp. 94–109, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. T. G. Bivona, H. Hieronymus, J. Parker et al., “FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR,” Nature, vol. 471, no. 7339, pp. 523–526, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. P. B. Chapman, A. Hauschild, C. Robert et al., “Improved survival with vemurafenib in melanoma with BRAF V600E mutation,” The New England Journal of Medicine, vol. 364, no. 26, pp. 2507–2516, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Hauschild, J.-J. Grob, L. V. Demidov et al., “Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial,” The Lancet, vol. 380, no. 9839, pp. 358–365, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. N. Wagle, E. M. Van Allen, D. J. Treacy et al., “MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition,” Cancer Discovery, vol. 4, no. 1, pp. 61–68, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Villanueva, J. R. Infante, C. Krepler et al., “Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma,” Cell Reports, vol. 4, no. 6, pp. 1090–1099, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Marchetti, M. Del Grammastro, G. Filice et al., “Complex mutations & subpopulations of deletions at exon 19 of EGFR in NSCLC revealed by next generation sequencing: potential clinical implications,” PLoS ONE, vol. 7, no. 7, Article ID e42164, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Marchetti, A. Ardizzoni, M. Papotti et al., “Recommendations for the analysis of ALK gene rearrangements in non-small-cell lung cancer: a consensus of the italian association of medical oncology and the Italian society of pathology and cytopathology,” Journal of Thoracic Oncology, vol. 8, no. 3, pp. 352–358, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Shen and P. W. Laird, “Interplay between the cancer genome and epigenome,” Cell, vol. 153, no. 1, pp. 38–55, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. L. G. Biesecker and N. B. Spinner, “A genomic view of mosaicism and human disease,” Nature Reviews Genetics, vol. 14, no. 5, pp. 307–320, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. J. G. Paez, P. A. Jänne, J. C. Lee et al., “EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy,” Science, vol. 304, no. 5676, pp. 1497–1500, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Malm, T. E. Fehniger, P. Danmyr et al., “Developments in biobanking workflow standardization providing sample integrity and stability,” Journal of Proteomics, vol. 95, pp. 38–45, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. G. da Cunha Santos, N. Liu, M.-S. Tsao, S. Kamel-Reid, K. Chin, and W. R. Geddie, “Detection of EGFR and KRAS mutations in fine-needle aspirates stored on whatman FTA cards: is this the tool for biobanking cytological samples in the molecular era?” Cancer Cytopathology, vol. 118, no. 6, pp. 450–456, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Subramaniam, R. K. Thakur, V. K. Yadav, R. Nanda, S. Chowdhury, and A. Agrawal, “Lung cancer biomarkers: state of the art,” Journal of Carcinogenesis, vol. 12, no. 3, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. M. G. Kris, R. B. Natale, R. S. Herbst et al., “Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial,” The Journal of the American Medical Association, vol. 290, no. 16, pp. 2149–2158, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Chi, S. Remick, and W. Tse, “EGFR inhibition in non-small cell lung cancer: current evidence and future directions,” Biomarker Research, vol. 1, article 2, 2013. View at Publisher · View at Google Scholar
  26. G. R. Oxnard, A. Binder, and P. A. Jänne, “New targetable oncogenes in non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 31, no. 8, pp. 1097–1104, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Liu, L.-C. Wu, J. Pang et al., “Sp1/NFκB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia,” Cancer Cell, vol. 17, no. 4, pp. 333–347, 2010. View at Publisher · View at Google Scholar
  28. G. Iyer, A. J. Hanrahan, M. I. Milowsky et al., “Genome sequencing identifies a basis for everolimus sensitivity,” Science, vol. 338, no. 6104, p. 221, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Shendure and H. Ji, “Next-generation DNA sequencing,” Nature Biotechnology, vol. 26, no. 10, pp. 1135–1145, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. B. M. Venkatesan and R. Bashir, “Nanopore sensors for nucleic acid analysis,” Nature Nanotechnology, vol. 6, no. 10, pp. 615–624, 2011. View at Google Scholar
  31. S. Valastyan and R. A. Weinberg, “Tumor metastasis: molecular insights and evolving paradigms,” Cell, vol. 147, no. 2, pp. 275–292, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. L. Wan, K. Pantel, and Y. Kang, “Tumor metastasis: moving new biological insights into the clinic,” Nature Medicine, vol. 19, no. 11, pp. 1450–1464, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. D. F. Quail and J. A. Joyce, “Microenvironmental regulation of tumor progression and metastasis,” Nature Medicine, vol. 19, no. 11, pp. 1423–1437, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. L.-M. Postovit, N. V. Margaryan, E. A. Seftor et al., “Human embryonic stem cell microenvironment suppresses the tumorigenic phenotype of aggressive cancer cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 11, pp. 4329–4334, 2008. View at Publisher · View at Google Scholar · View at Scopus
  35. F. G. Giancotti, “Mechanisms governing metastatic dormancy and reactivation,” Cell, vol. 155, no. 4, pp. 750–764, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. J. Chou, J. H. Lin, A. Brenot, J.-W. Kim, S. Provot, and Z. Werb, “GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression,” Nature Cell Biology, vol. 15, no. 2, pp. 201–213, 2013. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. Zhang, P. Yang, T. Sun et al., “miR-126 and miR-126 repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis,” Nature Cell Biology, vol. 15, no. 3, pp. 284–294, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. J. P. Thiery, “Epithelial-mesenchymal transitions in tumour progression,” Nature Reviews Cancer, vol. 2, no. 6, pp. 442–454, 2002. View at Publisher · View at Google Scholar
  39. D. M. Gonzalez and D. Medici, “Signaling mechanisms of the epithelial-mesenchymal transition,” Science Signaling, vol. 7, no. 344, p. re8, 2014. View at Publisher · View at Google Scholar · View at Scopus
  40. L. A. Byers, L. Diao, J. Wang et al., “An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance,” Clinical Cancer Research, vol. 19, no. 1, pp. 279–290, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. Z. Zhang, J. C. Lee, L. Lin et al., “Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer,” Nature Genetics, vol. 44, no. 8, pp. 852–860, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. D. C. Radisky and M. A. LaBarge, “Epithelial-mesenchymal transition and the stem cell phenotype,” Cell Stem Cell, vol. 2, no. 6, pp. 511–512, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. R. K. Ambasta, A. Sharma, and P. Kumar, “Nanoparticle mediated targeting of VEGFR and cancer stem cells for cancer therapy,” Vascular Cell, vol. 3, article 26, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. N. D. Marjanovic, R. A. Weinberg, and C. L. Chaffer, “Cell plasticity and heterogeneity in cancer,” Clinical Chemistry, vol. 59, no. 1, pp. 168–179, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. S. J. Vidal, V. Rodriguez-Bravo, M. Galsky, C. Cordon-Cardo, and J. Domingo-Domenech, “Targeting cancer stem cells to suppress acquired chemotherapy resistance,” Oncogene, vol. 33, no. 36, pp. 4451–4463, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. C. E. Eyler and J. N. Rich, “Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis,” Journal of Clinical Oncology, vol. 26, no. 17, pp. 2839–2845, 2008. View at Publisher · View at Google Scholar · View at Scopus
  47. H. Lou and M. Dean, “Targeted therapy for cancer stem cells: the patched pathway and ABC transporters,” Oncogene, vol. 26, no. 9, pp. 1357–1360, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. R. Morrison, S. M. Schleicher, Y. Sun et al., “Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis,” Journal of Oncology, vol. 2011, Article ID 941876, 13 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Vinogradov and X. Wei, “Cancer stem cells and drug resistance: the potential of nanomedicine,” Nanomedicine, vol. 7, no. 4, pp. 597–615, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. B. T. Kawasaki, E. M. Hurt, T. Mistree, and W. L. Farrar, “Targeting cancer stem cells with phytochemicals,” Molecular Interventions, vol. 8, no. 4, pp. 174–184, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. P. B. Gupta, T. T. Onder, G. Jiang et al., “Identification of selective inhibitors of cancer stem cells by high-throughput screening,” Cell, vol. 138, no. 4, pp. 645–659, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. Y. Zhao, D. Y. Alakhova, and A. V. Kabanov, “Can nanomedicines kill cancer stem cells?” Advanced Drug Delivery Reviews, vol. 65, no. 13-14, pp. 1763–1783, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. S. B. Baylin and P. A. Jones, “A decade of exploring the cancer epigenome—biological and translational implications,” Nature Reviews Cancer, vol. 11, no. 10, pp. 726–734, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. J. Sana, P. Faltejskova, M. Svoboda, and O. Slaby, “Novel classes of non-coding RNAs and cancer,” Journal of Translational Medicine, vol. 10, article 103, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Hui, C. How, E. Ito, and F.-F. Liu, “Micro-RNAs as diagnostic or prognostic markers in human epithelial malignancies,” BMC Cancer, vol. 11, article 500, 2011. View at Publisher · View at Google Scholar · View at Scopus
  56. S. Fukushige and A. Horii, “DNA methylation in cancer: a gene silencing mechanism and the clinical potential of its biomarkers,” Tohoku Journal of Experimental Medicine, vol. 229, no. 3, pp. 173–185, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. P. A. Jones, “Functions of DNA methylation: islands, start sites, gene bodies and beyond,” Nature Reviews Genetics, vol. 13, no. 7, pp. 484–492, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. A. G. Knudson Jr., “Mutation and cancer: statistical study of retinoblastoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 68, no. 4, pp. 820–823, 1971. View at Publisher · View at Google Scholar · View at Scopus
  59. G. A. Calin and C. M. Croce, “MicroRNA signatures in human cancers,” Nature Reviews Cancer, vol. 6, no. 11, pp. 857–866, 2006. View at Publisher · View at Google Scholar · View at Scopus
  60. S. Liu, “Epigenetics advancing personalized nanomedicine in cancer therapy,” Advanced Drug Delivery Reviews, vol. 64, no. 13, pp. 1532–1543, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. T. F. Gajewski, “Molecular profiling of melanoma and the evolution of patient-specific therapy,” Seminars in Oncology, vol. 38, no. 2, pp. 236–242, 2011. View at Publisher · View at Google Scholar · View at Scopus
  62. K. L. Nathanson, “Using genetics and genomics strategies to personalize therapy for cancer: focus on melanoma,” Biochemical Pharmacology, vol. 80, no. 5, pp. 755–761, 2010. View at Publisher · View at Google Scholar · View at Scopus
  63. P. V. Jithesh, J. M. Risk, A. G. Schache et al., “The epigenetic landscape of oral squamous cell carcinoma,” British Journal of Cancer, vol. 108, no. 2, pp. 370–379, 2013. View at Publisher · View at Google Scholar · View at Scopus
  64. J. R. Schoenborn, P. Nelson, and M. Fang, “Genomic profiling defines subtypes of prostate cancer with the potential for therapeutic stratification,” Clinical Cancer Research, vol. 19, no. 15, pp. 4058–4066, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. D. S. Uppal and S. M. Powell, “Genetics/genomics/proteomics of gastric adenocarcinoma,” Gastroenterology Clinics of North America, vol. 42, no. 2, pp. 241–260, 2013. View at Publisher · View at Google Scholar · View at Scopus
  66. C. P. Lange and P. W. Laird, “Clinical applications of DNA methylation biomarkers in colorectal cancer,” Epigenomics, vol. 5, no. 2, pp. 105–108, 2013. View at Publisher · View at Google Scholar · View at Scopus
  67. H. Kim, K. Kim, S. J. Yu et al., “Development of biomarkers for screening hepatocellular carcinoma using global data mining and multiple reaction monitoring,” PLoS ONE, vol. 8, no. 5, Article ID e63468, 2013. View at Publisher · View at Google Scholar · View at Scopus
  68. M. Chmelarová, E. Dvoráková, J. Špacek, J. Laco, M. MŽik, and V. Palicka, “Promoter methylation of GATA4, WIF1, NTRK1 and other selected tumour suppressor genes in ovarian cancer,” Folia Biologica, vol. 59, no. 2, pp. 87–92, 2013. View at Google Scholar · View at Scopus
  69. A. I. Ojesina, L. Lichtenstein, S. S. Freeman et al., “Landscape of genomic alterations in cervical carcinomas,” Nature, vol. 506, no. 7488, pp. 371–375, 2013. View at Publisher · View at Google Scholar
  70. A. Q. van Hoesel, Y. Sato, D. A. Elashoff et al., “Assessment of DNA methylation status in early stages of breast cancer development,” British Journal of Cancer, vol. 108, no. 10, pp. 2033–2038, 2013. View at Publisher · View at Google Scholar · View at Scopus
  71. A. I. Oliveira, C. Jerónimo, and R. Henrique, “Moving forward in bladder cancer detection and diagnosis: the role of epigenetic biomarkers,” Expert Review of Molecular Diagnostics, vol. 12, no. 8, pp. 871–878, 2012. View at Publisher · View at Google Scholar · View at Scopus
  72. S. Markopoulou, G. Nikolaidis, and T. Liloglou, “DNA methylation biomarkers in biological fluids for early detection of respiratory tract cancer,” Clinical Chemistry and Laboratory Medicine, vol. 50, no. 10, pp. 1723–1731, 2012. View at Publisher · View at Google Scholar · View at Scopus
  73. K. A. Heichman and J. D. Warren, “DNA methylation biomarkers and their utility for solid cancer diagnostics,” Clinical Chemistry and Laboratory Medicine, vol. 50, no. 10, pp. 1707–1721, 2012. View at Publisher · View at Google Scholar · View at Scopus
  74. J. K. Samuelsson, S. Alonso, F. Yamamoto, and M. Perucho, “DNA fingerprinting techniques for the analysis of genetic and epigenetic alterations in colorectal cancer,” Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, vol. 693, no. 1-2, pp. 61–76, 2010. View at Publisher · View at Google Scholar · View at Scopus
  75. G. S. Inamdar, S. V. Madhunapantula, and G. P. Robertson, “Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail,” Biochemical Pharmacology, vol. 80, no. 5, pp. 624–637, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. J. A. Gasche and A. Goel, “Epigenetic mechanisms in oral carcinogenesis,” Future Oncology, vol. 8, no. 11, pp. 1407–1425, 2012. View at Publisher · View at Google Scholar · View at Scopus
  77. D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: the next generation,” Cell, vol. 144, no. 5, pp. 646–674, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. J. B. Rawson and B. Bapat, “Epigenetic biomarkers in colorectal cancer diagnostics,” Expert Review of Molecular Diagnostics, vol. 12, no. 5, pp. 499–509, 2012. View at Publisher · View at Google Scholar · View at Scopus
  79. M. Berg and K. Søreide, “Genetic and epigenetic traits as biomarkers in colorectal cancer,” International Journal of Molecular Sciences, vol. 12, no. 12, pp. 9426–9439, 2011. View at Publisher · View at Google Scholar · View at Scopus
  80. M.-A. Song, M. Tiirikainen, S. Kwee, G. Okimoto, H. Yu, and L. L. Wong, “Elucidating the landscape of aberrant DNA methylation in hepatocellular carcinoma,” PLoS ONE, vol. 8, no. 2, Article ID e55761, 2013. View at Publisher · View at Google Scholar · View at Scopus
  81. A. Fujimoto, Y. Totoki, T. Abe et al., “Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators,” Nature Genetics, vol. 44, no. 7, pp. 760–764, 2012. View at Publisher · View at Google Scholar · View at Scopus
  82. C. Ozen, G. Yildiz, A. T. Dagcan et al., “Genetics and epigenetics of liver cancer,” New Biotechnology, vol. 30, no. 4, pp. 381–384, 2013. View at Publisher · View at Google Scholar · View at Scopus
  83. G. Diaz, M. Melis, A. Tice et al., “Identification of microRNAs specifically expressed in hepatitis C virus-associated hepatocellular carcinoma,” International Journal of Cancer, vol. 133, no. 4, pp. 816–824, 2013. View at Publisher · View at Google Scholar · View at Scopus
  84. L. E. De Faveri, C. D. Hurst, F. M. Platt et al., “Putative tumour suppressor gene necdin is hypermethylated and mutated in human cancer,” British Journal of Cancer, vol. 108, no. 6, pp. 1368–1377, 2013. View at Publisher · View at Google Scholar · View at Scopus
  85. Y. Gui, G. Guo, Y. Huang et al., “Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder,” Nature Genetics, vol. 43, no. 9, pp. 875–878, 2011. View at Publisher · View at Google Scholar
  86. B. R. Druliner, J. A. Fincher, B. S. Sexton et al., “Chromatin patterns associated with lung adenocarcinoma progression,” Cell Cycle, vol. 12, no. 10, pp. 1536–1543, 2013. View at Publisher · View at Google Scholar · View at Scopus
  87. P. K. Vogt, “Retroviral oncogenes: a historical primer,” Nature Reviews Cancer, vol. 12, no. 9, pp. 639–648, 2012. View at Publisher · View at Google Scholar · View at Scopus
  88. T. Soussi, “Advances in carcinogenesis: a historical perspective from observational studies to tumor genome sequencing and TP53 mutation spectrum analysis,” Biochimica et Biophysica Acta—Reviews on Cancer, vol. 1816, no. 2, pp. 199–208, 2011. View at Publisher · View at Google Scholar · View at Scopus
  89. A. J. Bass, M. S. Lawrence, L. E. Brace et al., “Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion,” Nature Genetics, vol. 43, no. 10, pp. 964–970, 2011. View at Publisher · View at Google Scholar · View at Scopus
  90. A. Kreso, C. A. O'Brien, P. van Galen et al., “Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer,” Science, vol. 339, no. 6119, pp. 543–548, 2013. View at Publisher · View at Google Scholar · View at Scopus
  91. D. Singh, J. M. Chan, P. Zoppoli et al., “Transforming fusions of FGFR and TACC genes in human glioblastoma,” Science, vol. 337, no. 6099, pp. 1231–1235, 2012. View at Publisher · View at Google Scholar · View at Scopus
  92. S. Seton-Rogers, “Glioblastoma: transforming fusions induce aneuploidy,” Nature Reviews Cancer, vol. 12, no. 9, article 585, 2012. View at Publisher · View at Google Scholar · View at Scopus
  93. V. Frattini, V. Trifonov, J. M. Chan et al., “The integrated landscape of driver genomic alterations in glioblastoma,” Nature Genetics, vol. 45, no. 10, pp. 1141–1149, 2013. View at Publisher · View at Google Scholar · View at Scopus
  94. P. A. Northcott, D. J. Shih, J. Peacock et al., “Subgroup-specific structural variation across 1,000 medulloblastoma genomes,” Nature, vol. 488, no. 7409, pp. 49–56, 2012. View at Google Scholar
  95. G. P. Tonini, A. Nakagawara, and F. Berthold, “Towards a turning point of neuroblastoma therapy,” Cancer Letters, vol. 326, no. 2, pp. 128–134, 2012. View at Publisher · View at Google Scholar · View at Scopus
  96. M. Capasso, M. Devoto, C. Hou et al., “Common variations in BARD1 influence susceptibility to high-risk neuroblastoma,” Nature Genetics, vol. 41, no. 6, pp. 718–723, 2009. View at Publisher · View at Google Scholar · View at Scopus
  97. K. Wang, S. J. Diskin, H. Zhang et al., “Integrative genomics identifies LMO1 as a neuroblastoma oncogene,” Nature, vol. 469, no. 7329, pp. 216–220, 2011. View at Publisher · View at Google Scholar · View at Scopus
  98. M. Sausen, R. J. Leary, S. Jones et al., “Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma,” Nature Genetics, vol. 45, no. 1, pp. 12–17, 2013. View at Publisher · View at Google Scholar · View at Scopus
  99. B. Banelli, D. F. Merlo, G. Allemanni, A. Forlani, and M. Romani, “Clinical potentials of methylator phenotype in stage 4 high-risk neuroblastoma: an open challenge,” PLoS ONE, vol. 8, no. 5, Article ID e63253, 2013. View at Publisher · View at Google Scholar · View at Scopus
  100. L. Van Neste, J. G. Herman, G. Otto, J. W. Bigley, J. I. Epstein, and W. Van Criekinge, “The epigenetic promise for prostate cancer diagnosis,” Prostate, vol. 72, no. 11, pp. 1248–1261, 2012. View at Publisher · View at Google Scholar · View at Scopus
  101. H.-Y. Yoon, Y.-W. Kim, H. W. Kang et al., “Pyrosequencing analysis of APC methylation level in human prostate tissues: a molecular marker for prostate cancer,” Korean Journal of Urology, vol. 54, no. 3, pp. 194–198, 2013. View at Publisher · View at Google Scholar · View at Scopus
  102. M. Ilie, V. Hofman, E. Long et al., “Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine?” Annals of Translational Medicine, vol. 2, no. 11, p. 107, 2014. View at Publisher · View at Google Scholar
  103. M. Ilie, V. Hofman, E. Long-Mira et al., “‘Sentinel’ circulating tumor cells allow early diagnosis of lung cancer in patients with Chronic obstructive pulmonary disease,” PLoS ONE, vol. 9, no. 10, Article ID e111597, 2014. View at Publisher · View at Google Scholar · View at Scopus
  104. Y. J. Zhao, Q. Ju, and G. C. Li, “Tumor markers for hepatocellular carcinoma,” Molecular and Clinical Oncology, vol. 1, no. 4, pp. 593–598, 2013. View at Google Scholar
  105. S.-Y. Liao, O. N. Aurelio, K. Jan, J. Zavada, and E. J. Stanbridge, “Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney,” Cancer Research, vol. 57, no. 14, pp. 2827–2831, 1997. View at Google Scholar · View at Scopus
  106. J. J. Morrissey, A. N. London, J. Luo, and E. D. Kharasch, “Urinary biomarkers for the early diagnosis of kidney cancer,” Mayo Clinic Proceedings, vol. 85, no. 5, pp. 413–421, 2010. View at Publisher · View at Google Scholar · View at Scopus
  107. D. Su Kim, Y. D. Choi, M. Moon et al., “Composite three-marker assay for early detection of kidney cancer,” Cancer Epidemiology Biomarkers and Prevention, vol. 22, no. 3, pp. 390–398, 2013. View at Publisher · View at Google Scholar · View at Scopus
  108. H. Abe and T. Kamai, “Recent advances in the treatment of metastatic renal cell carcinoma,” International Journal of Urology, vol. 20, no. 10, pp. 944–955, 2013. View at Publisher · View at Google Scholar · View at Scopus
  109. S. G. C. Kroeze, A. M. Bijenhof, J. L. H. R. Bosch, and J. J. M. Jans, “Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma,” Cancer Biomarkers, vol. 7, no. 6, pp. 261–268, 2010. View at Publisher · View at Google Scholar · View at Scopus
  110. L. J. Costa and H. A. Drabkin, “Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies,” Oncologist, vol. 12, no. 12, pp. 1404–1415, 2007. View at Publisher · View at Google Scholar · View at Scopus
  111. M. Wehland, J. Bauer, N. E. Magnusson, M. Infanger, and D. Grimm, “Biomarkers for anti-angiogenic therapy in cancer,” International Journal of Molecular Sciences, vol. 14, no. 5, pp. 9338–9364, 2013. View at Publisher · View at Google Scholar · View at Scopus
  112. W. G. Kaelin Jr., “The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma,” Clinical Cancer Research, vol. 13, no. 2, part 2, pp. 680s–684s, 2007. View at Publisher · View at Google Scholar · View at Scopus
  113. Cancer Genome Atlas Research Network, “Comprehensive molecular characterization of clear cell renal cell carcinoma,” Nature, vol. 499, no. 7456, pp. 43–49, 2013. View at Publisher · View at Google Scholar
  114. A. A. Hakimi, I. Ostrovnaya, B. Reva et al., “Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network,” Clinical Cancer Research, vol. 19, no. 12, pp. 3259–3267, 2013. View at Publisher · View at Google Scholar · View at Scopus
  115. P. S. Mitchell, R. K. Parkin, E. M. Kroh et al., “Circulating microRNAs as stable blood-based markers for cancer detection,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 30, pp. 10513–10518, 2008. View at Publisher · View at Google Scholar · View at Scopus
  116. C. H. Lawrie, S. Gal, H. M. Dunlop et al., “Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma,” British Journal of Haematology, vol. 141, no. 5, pp. 672–675, 2008. View at Publisher · View at Google Scholar · View at Scopus
  117. H. Qu, W. Xu, Y. Huang, and S. Yang, “Circulating miRNAs: promising biomarkers of human cancer,” Asian Pacific Journal of Cancer Prevention, vol. 12, no. 5, pp. 1117–1125, 2011. View at Google Scholar · View at Scopus
  118. S. Valastyan and R. A. Weinberg, “MicroRNAs: crucial multi-tasking components in the complex circuitry of tumor metastasis,” Cell Cycle, vol. 8, no. 21, pp. 3506–3512, 2009. View at Publisher · View at Google Scholar · View at Scopus
  119. D. Zheng, S. Haddadin, Y. Wang et al., “Plasma microRNAs as novel biomarkers for early detection of lung cancer,” International Journal of Clinical and Experimental Pathology, vol. 4, no. 6, pp. 575–586, 2011. View at Google Scholar
  120. H. Zheng, L. Zhang, Y. Zhao et al., “Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer,” PLoS ONE, vol. 8, no. 11, Article ID e77853, 2013. View at Publisher · View at Google Scholar · View at Scopus
  121. Y. Zhang, D. Yang, L. Weng, and L. Wang, “Early lung cancer diagnosis by biosensors,” International Journal of Molecular Sciences, vol. 14, no. 8, pp. 15479–15509, 2013. View at Publisher · View at Google Scholar · View at Scopus
  122. M. A. Cortez, J. W. Welsh, and G. A. Calin, “Circulating MicroRNAs as noninvasive biomarkers in breast cancer,” Recent Results in Cancer Research, vol. 195, pp. 151–161, 2012. View at Publisher · View at Google Scholar · View at Scopus
  123. H. Schwarzenbach, N. Nishida, G. A. Calin, and K. Pantel, “Clinical relevance of circulating cell-free microRNAs in cancer,” Nature Reviews Clinical Oncology, vol. 11, no. 3, pp. 145–156, 2014. View at Publisher · View at Google Scholar · View at Scopus
  124. E. Heitzer, P. Ulz, and J. B. Geigl, “Circulating tumor DNA as a liquid biopsy for cancer,” Clinical Chemistry, vol. 61, no. 1, pp. 112–123, 2015. View at Publisher · View at Google Scholar · View at Scopus
  125. D. Peer, J. M. Karp, S. Hong, O. C. Farokhzad, R. Margalit, and R. Langer, “Nanocarriers as an emerging platform for cancer therapy,” Nature Nanotechnology, vol. 2, no. 12, pp. 751–760, 2007. View at Publisher · View at Google Scholar · View at Scopus
  126. D. J. Bharali and S. A. Mousa, “Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise,” Pharmacology and Therapeutics, vol. 128, no. 2, pp. 324–335, 2010. View at Publisher · View at Google Scholar · View at Scopus
  127. Y.-E. Choi, J.-W. Kwak, and J. W. Park, “Nanotechnology for early cancer detection,” Sensors, vol. 10, no. 1, pp. 428–455, 2010. View at Publisher · View at Google Scholar · View at Scopus
  128. R. Ranganathan, S. Madanmohan, A. Kesavan et al., “Nanomedicine: towards development of patient-friendly drug-delivery systems for oncological applications,” International Journal of Nanomedicine, vol. 7, pp. 1043–1060, 2012. View at Publisher · View at Google Scholar · View at Scopus
  129. Y. Hu, D. H. Fine, E. Tasciotti, A. Bouamrani, and M. Ferrari, “Nanodevices in diagnostics,” Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, vol. 3, no. 1, pp. 11–32, 2011. View at Publisher · View at Google Scholar · View at Scopus
  130. E.-K. Lim, E. Jang, K. Lee, S. Haam, and Y.-M. Huh, “Delivery of cancer therapeutics using nanotechnology,” Pharmaceutics, vol. 5, no. 2, pp. 294–317, 2013. View at Publisher · View at Google Scholar · View at Scopus
  131. I. E. Tothill, “Biosensors for cancer markers diagnosis,” Seminars in Cell and Developmental Biology, vol. 20, no. 1, pp. 55–62, 2009. View at Publisher · View at Google Scholar · View at Scopus
  132. K. K. Jain, “Advances in the field of nanooncology,” BMC Medicine, vol. 8, article 83, 2010. View at Publisher · View at Google Scholar · View at Scopus
  133. X. Qian, X.-H. Peng, D. O. Ansari et al., “In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags,” Nature Biotechnology, vol. 26, no. 1, pp. 83–90, 2008. View at Publisher · View at Google Scholar · View at Scopus
  134. J. Aaron, N. Nitin, K. Travis et al., “Plasmon resonance coupling of metal nanoparticles for molecular imaging of carcinogenesis in vivo,” Journal of Biomedical Optics, vol. 12, no. 3, Article ID 034007, 2007. View at Publisher · View at Google Scholar · View at Scopus
  135. I. H. El-Sayed, X. Huang, and M. A. El-Sayed, “Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles,” Cancer Letters, vol. 239, no. 1, pp. 129–135, 2006. View at Publisher · View at Google Scholar · View at Scopus
  136. X. Liu, Q. Dai, L. Austin et al., “A one-step homogeneous immunoassay for cancer biomarker detection using gold nanoparticle probes coupled with dynamic light scattering,” Journal of the American Chemical Society, vol. 130, no. 9, pp. 2780–2782, 2008. View at Publisher · View at Google Scholar · View at Scopus
  137. V. Mani, B. V. Chikkaveeraiah, V. Patel, J. S. Gutkind, and J. F. Rusling, “Ultrasensitive immunosensor for cancer biomarker proteins using gold nanoparticle film electrodes and multienzyme-particle amplification,” ACS Nano, vol. 3, no. 3, pp. 585–594, 2009. View at Publisher · View at Google Scholar · View at Scopus
  138. M. Soster, R. Juris, S. Bonacchi et al., “Targeted dual-color silica nanoparticles provide univocal identification of micrometastases in preclinical models of colorectal cancer,” International Journal of Nanomedicine, vol. 7, pp. 4797–4807, 2012. View at Publisher · View at Google Scholar · View at Scopus
  139. H. Lee, E. Sun, D. Ham, and R. Weissleder, “Chip-NMR biosensor for detection and molecular analysis of cells,” Nature Medicine, vol. 14, no. 8, pp. 869–874, 2008. View at Publisher · View at Google Scholar · View at Scopus
  140. S. Y. Madani, F. Shabani, M. V. Dwek, and A. M. Seifalian, “Conjugation of quantum dots on carbon nanotubes for medical diagnosis and treatment,” International Journal of Nanomedicine, vol. 8, pp. 941–950, 2013. View at Publisher · View at Google Scholar · View at Scopus
  141. J. Clarke, H.-C. Wu, L. Jayasinghe, A. Patel, S. Reid, and H. Bayley, “Continuous base identification for single-molecule nanopore DNA sequencing,” Nature Nanotechnology, vol. 4, no. 4, pp. 265–270, 2009. View at Publisher · View at Google Scholar · View at Scopus
  142. M. Das, D. Mishra, P. Dhak et al., “Biofunctionalized, phosphonate-grafted, ultrasmall iron oxide nanoparticles for combined targeted cancer therapy and multimodal imaging,” Small, vol. 5, no. 24, pp. 2883–2893, 2009. View at Publisher · View at Google Scholar · View at Scopus
  143. S. K. Arya and S. Bhansali, “Lung cancer and its early detection using biomarker-based biosensors,” Chemical Reviews, vol. 111, no. 11, pp. 6783–6809, 2011. View at Publisher · View at Google Scholar · View at Scopus
  144. J. C. Brase, D. Wuttig, R. Kuner, and H. Sültmann, “Serum microRNAs as non-invasive biomarkers for cancer,” Molecular Cancer, vol. 9, p. 306, 2010. View at Publisher · View at Google Scholar · View at Scopus
  145. D. Barh, A. Carpi, M. Verma et al., Cancer Biomarkers: Minimal and Noninvasive Early Diagnosis and Prognosis, CRC Press, Boca Raton, Fla, USA, 2014.
  146. K. T. Adams, “Ups and downs at ASCO 2014,” Managed Care, vol. 23, no. 8, pp. 50–52, 2014. View at Google Scholar · View at Scopus
  147. D. Siolas and G. J. Hannon, “Patient-derived tumor xenografts: transforming clinical samples into mouse models,” Cancer Research, vol. 73, no. 17, pp. 5315–5319, 2013. View at Publisher · View at Google Scholar · View at Scopus
  148. A. Gdowski, A. P. Ranjan, A. Mukerjee, and J. K. Vishwanatha, “Nanobiosensors: role in cancer detection and diagnosis,” Advances in Experimental Medicine and Biology, vol. 807, pp. 33–58, 2014. View at Publisher · View at Google Scholar · View at Scopus
  149. L. Saenz del Burgo, J. L. Pedraz, and G. Orive, “Advanced nanovehicles for cancer management,” Drug Discovery Today, vol. 19, no. 10, pp. 1659–1670, 2014. View at Publisher · View at Google Scholar · View at Scopus
  150. V. Sanna, N. Pala, and M. Sechi, “Targeted therapy using nanotechnology: focus on cancer,” International Journal of Nanomedicine, vol. 9, no. 1, pp. 467–483, 2014. View at Publisher · View at Google Scholar · View at Scopus
  151. J. Chen, R. Shao, X. D. Zhang et al., “Applications of nanotechnology for melanoma treatment, diagnosis, and theranostics,” International Journal of Nanomedicine, vol. 8, pp. 2677–2688, 2013. View at Google Scholar
  152. C. Esposito, A. Crema, A. Ponzetto, G. Murtas, and G. Carloni, “Multifunctional anti-cancer nano-platforms are moving to clinical trials,” Current Drug Metabolism, vol. 14, no. 5, pp. 583–604, 2013. View at Publisher · View at Google Scholar · View at Scopus
  153. M. S. Muthu, D. T. Leong, L. Mei, and S.-S. Feng, “Nanotheranostics—application and further development of nanomedicine strategies for advanced theranostics,” Theranostics, vol. 4, no. 6, pp. 660–677, 2014. View at Publisher · View at Google Scholar · View at Scopus
  154. A. R. Burke, R. N. Singh, D. L. Carroll, F. M. Torti, and S. V. Torti, “Targeting cancer stem cells with nanoparticle-enabled therapies,” Journal of Molecular Biomarkers & Diagnosis, supplement 8, 2012. View at Publisher · View at Google Scholar
  155. M. K. Yu, J. Park, and S. Jon, “Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy,” Theranostics, vol. 2, no. 1, pp. 3–44, 2012. View at Publisher · View at Google Scholar · View at Scopus